Truist Securities Maintains Buy Rating for Immunogen: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Truist Securities maintains its Buy rating for Immunogen (NASDAQ: IMGN) and raises its price target from $15.00 to $18.00. Shares of Immunogen are currently trading down 2.6% at $14.97 per share.
June 06, 2023 | 5:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities maintains Buy rating for Immunogen (NASDAQ: IMGN) and raises its price target from $15.00 to $18.00, a potential 20.24% increase from the current share price.
Truist Securities' decision to maintain a Buy rating and raise the price target for Immunogen indicates a positive outlook for the stock. This could lead to increased investor interest and a potential short-term increase in the stock price. However, the stock is currently trading down 2.6%, which may be a temporary reaction to other market factors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100